liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Frequent non-cardiac comorbidities in patients with chronic heart failure
Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Care, Cardiology. Östergötlands Läns Landsting, Heart Centre, Department of Cardiology.ORCID iD: 0000-0001-6353-8041
2005 (English)In: European Journal of Heart Failure, ISSN 1388-9842, Vol. 7, no 3 SPEC. ISS., 309-316 p.Article in journal (Refereed) Published
Abstract [en]

Heart failure (HF) in elderly patients is associated with more diffuse symptoms and signs due to the presence of other noncardiac comorbidities. This can cause difficulties in assessing the correct diagnosis and initiating appropriate therapy. The four most frequently occurring noncardiac comorbidities and therapies used to treat them are discussed in the present paper. Hypertension is an important precursor of HF, and is still the most common risk factor for HF in the general population. About 50% of patients with untreated hypertension will develop HF. Pressure overload leads to the development of left ventricular hypertrophy (LVH) and diastolic dysfunction. Diabetes, which occurs in about 20-30% of patients with HF, is an important comorbidity resulting in morphological and metabolic disturbances affecting myocardial blood flow and hormonal regulation leading to a poor outcome and necessitating aggressive conventional treatment. Chronic obstructive pulmonary disease (COPD), occurs in approximately 20-30% of heart failure patients, and may complicate HF treatment, it is therefore important to recognize and treat it effectively. Finally, the early detection of anemia, which occurs in 20-30% of HF patients, is important since it is associated with functional impairment and increased mortality and morbidity. Combined treatment with erythropoietin and intravenous iron has shown beneficial effects on clinical symptoms and morbidity. In conclusion early detection of concomitant diseases in patients with HF is important and should be considered carefully when initiating therapy. © 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.

Place, publisher, year, edition, pages
2005. Vol. 7, no 3 SPEC. ISS., 309-316 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-33740DOI: 10.1016/j.ejheart.2005.01.008Local ID: 19782OAI: diva2:254563
Available from: 2009-10-09 Created: 2009-10-09 Last updated: 2013-09-26

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Dahlström, Ulf
By organisation
Faculty of Health SciencesCardiologyDepartment of Cardiology
In the same journal
European Journal of Heart Failure
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 37 hits
ReferencesLink to record
Permanent link

Direct link